


Viral Suppression in CSF and Genital Tract on ATV/r-only Maintenance (ATARITMO-Study)

P. Vernazza, S. Daneel, V. Schiffer, L. Decosterd, B.
Hirschel, and the Swiss HIV Cohort S.







Long-term consequences of NRTI

CHANGES IN MITOCHONDRIAL DNA AS A MARKER OF NUCLEOSIDE TOXICITY IN HIV-INFECTED PATIENTS


HÉLÈNE C.F. CÔTÉ, PH.D., ZABRINA
BRIAN WYNHOVEN, B.S., LILLIAN TING
MICHAEL V.

Mitochondrial DNA dec
tissue of HIV-infected
lip

Cecilia M. Shikuma^{ab}, Ningj
Carol Waslien^d, Sheri S



Breakthrough: boosting PI's




Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection

Christian Kahlert^{a,c}, Maria Hupfer^a, Thomas Wagels^a, Daniel Bueche^b, Walter Fierz^c, Ulrich A. Walker^d and Pietro L. Vernazza^a

- **48 weeks pilot study**
- **12 patients with VL < 50cp/ml**
- **Test the concept of PI only**

IDV/r Mono: 48 week results

Level of HIV-RNA Suppression



ATARITMO: ATV/rit Mono-Trial

- **Pilot Study: 30 Pat planned**
 - A) 9 patients continued from IDV/r mono-trial
 - B) 21 patients with tripple HAART
- **VL<50, no previous ART failure**
- **24 week: monthly ultrasens. HIV-RNA**
- **Compartment evaluation**
 - HIV-RNA and AZV levels in CSF (w24)
 - HIV-RNA in seminal plasma (w24)
- **Metabolic evaluation (Dexa, GTT, Lipids)**

Definition for treatment failure

- **2 consecutive HIV-RNA > 400 cp/ml**
- **3 consecutive HIV-RNA > 200 cp/ml**
- **4 consecutive HIV-RNA > 100 cp/ml**

Interim Results (July 2005)

- **Patients enrolled:** **28** (25 m)
- **Patients reached wk24** **24**
 - **Failing >400cp/ml (n/%)** **2 / (8%)**
 - 1 Pat. stopped Tx at wk 20
 - 1 Pat. failed w8: Previous IDV failure
 - **Pat. w. Blips >100cp/ml (n/%)** **5 / (21%)**


Semen / CSF results

- Patient passed wk24 24
- Patient with HIV-RNA < 50 22*


• Semen samples	n	%>100 cp/ml
– BL:	15	2 (110; 110)
– Wk 24	12	2 (170; 170)

• CSF samples	n	%>100 cp/ml
– BL (only in IDV/r)	5	2 (500; 1700)
– Wk24	12	2 (130; 700)

Sanctuaries: CSF and Semen



Pre-Therapy / Mono-Therapy (n=28)



Lessons for future Mono-trials

- **ATV/r is a feasible option for further monotherapy trials**
- **Carfully obtain treatment hx
→ exclude previous failures**
- **Compartment issues should be carefully monitored in future mono-therapy trials**
- **PI/r-monotherapy ONLY in clinical trials**
- **Long term success of PI/r mono remains tbd**

Acknowledgement

- **Synove Daneel**
Christian Kahlert
Maria Hupfer
Patrick Schmid
- **Sylvane Bottone**
Veronique Schiffer
Bernard Hirschel
- **Thomas Klimkait**
- **Detlev Schultze**

